Arxx Therapeutics initiates first-in-human trial of AX-202 – a monoclonal antibody under development for fibrotic diseases

The first subjects have been successfully dosed with AX-202 at The Medicines Evaluation Unit in Manchester UK In this phase 1 trial, Arxx Therapeutic’s monoclonal antibody AX-202 is being tested in healthy volunteers and patients with psoriasis, leading into Arxx’s program in systemic sclerosis   Oslo, Norway, 8 May 2023 – Arxx Therapeutics, a Norwegian-Danish […]

Arxx Therapeutics appoints Øystein Soug as CEO

Oslo, May 18, 2022: The Board of Arxx Therapeutics AS, a biotechnology company pioneering the development of novel therapeutics for fibrotic disease, today announced the appointment of Øystein Soug as CEO, effective today. Øystein Soug comes from Targovax ASA, an Oslo Stock Exchange listed biotechnology company, where he has served as CEO of Targovax since […]

Arxx Therapeutics to sponsor Scleroderma & Raynaud’s UK's (SRUK) Virtual Conference

Arxx Therapeutics is sponsoring Scleroderma & Raynaud’s UK's (SRUK) Virtual Conference September 11th 2021. Scleroderma & Raynaud’s UK (SRUK) is the only UK Charity dedicated to improving the lives of people with scleroderma and Raynaud’s phenomenon. The Virtual Conference is lead by world leading medical experts and will be covering a whole range of information […]

In vivo Proof-of-Concept of AX-202 presented at EULAR 2021 by Dr. Michal Tomčík

Anti-S100A4 monoclonal antibody treatment ameliorates skin fibrosis in inflammatory and noninflammatory pre-clinical models of systemic sclerosis

Arxx Therapeutics Secures NOK110 Million in Seed Round

Funding to support clinical phase 1 readiness

Get in touch

    We are dedicated to developing transformative therapies for patients with fibrotic disease.
    We believe that AX-202 has the potential to transform how fibrosis is treated and help many patients poorly served by current therapeutic options.
    Arxx Therapeutics
    in Norway: Gaustadalléen 21, 0349 Oslo
    in Denmark: Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen 
    © 2021 Arxx Therapeutics. All rights reserved. | Privacy Policy